Evidence map›Paper›PMID 40757033›Full record

ArticleFrontiers in neurology2025

Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms.

Nikita A van de Burgt, Laila Kulsvehagen, Marina Mané-Damas, Luc Lutz, Anne-Catherine Lecourt, Clara Monserrat, Anita M Vinke, Cem I Küçükali, Shenghua Zong, Carolin Hoffmann and 13 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nikita A van de Burgt *Department of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Laila Kulsvehagen *Departments of Neurology, Biomedicine, and Clinical Research, and Research Center for Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
Marina Mané-DamasDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Luc LutzDepartments of Neurology, Biomedicine, and Clinical Research, and Research Center for Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
Anne-Catherine LecourtDepartments of Neurology, Biomedicine, and Clinical Research, and Research Center for Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
Clara MonserratInstitut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
Anita M VinkeDepartment of Neurology, Maastricht University Medical Centre (MUMC+), Maastricht, Netherlands.
Cem I KüçükaliDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye.
Shenghua ZongDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Carolin HoffmannABC-RI, Algarve Biomedical Center Research Institute, Universidade do Algarve, Faro, Portugal.
Emiliano González-VioqueDepartment of Child and Adolescent Psychiatry, Hospital General Universitario, Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
Celso ArangoDepartment of Child and Adolescent Psychiatry, Hospital General Universitario, Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
Nicole K LeiboldDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Mario LosenDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Peter C MolenaarDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Erdem TüzünDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye.
Nico J M van BeverenDepartment of Psychiatry, Erasmus Medical Center, Rotterdam, Netherlands.
Anna ManéInstitut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
Rob P W RouhlMental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
Therese A M J van AmelsvoortDepartment of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.
for Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Anne-Katrin Pröbstel *Departments of Neurology, Biomedicine, and Clinical Research, and Research Center for Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
Pilar Martinez-Martinez *Department of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of autoantibodies against myelin oligodendrocyte glycoprotein (MOG) is a hallmark of MOG antibody-associated disease (MOGAD), a recently defined demyelinating disease entity presenting with core clinical features of optic neuritis, myelitis, and acute disseminated encephalomyelitis. Although MOG antibodies have also been described in a small number of patients with other conditions, including mental disorders, their prevalence and clinical specificity in patients with isolated psychotic symptoms remain unclear. Here, we screened sera from 262 patients with at least one psychotic episode and 166 control subjects for the presence of MOG antibodies of the immunoglobulin G (IgG) isotype with a live cell-based assay. Serum reactivity to additional antigens was assessed by immunohistochemistry. Four patients, representing 1.5% of the patient cohort, and one control individual, representing. 0.6% of the healthy control cohort, were seropositive for MOG-IgG antibodies. Of the four MOG-IgG seropositive patients, three experienced visual hallucinations. Overall, MOG antibodies were detected at a low frequency in patients with psychotic episodes. While we cannot exclude the possibility of false-positive results or seroconversion due to secondary myelin damage, the association with visual hallucinations in three out of four MOG-IgG seropositive patients may point toward an underlying autoimmune etiology.

Indexed as

autoantibodiesmental disordersmyelin oligodendrocyte glycoprotein antibody-associated diseaseneuroinflammationpsychiatrypsychosis

Identifiers

PMID40757033
PMCPMC12316182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.